Hutchinson Technology Announces CE Mark Of The InSpectra(TM) StO2 Spot Check
HUTCHINSON, Minn., Dec. 9, 2010 (GLOBE NEWSWIRE) -- Hutchinson Technology Incorporated (Nasdaq:HTCH) today announced CE Mark and the market launch of the InSpectra™ StO2 Spot Check for use as a noninvasive, cost-effective tool to rapidly assess the tissue oxygenation of patients in circulatory distress. The product, which is targeted for use in emergency and critical care environments, is now available in countries that recognize the CE Mark. The company also has filed for marketing clearance of the product in the United States under the U.S. Food and Drug Administration's Premarket Notification, or 510(k), process.
A photo accompanying this release is available at http://www.globenewswire.com/newsroom/prs/?pkgid=8409
The InSpectra StO2 Spot Check (model 300) consists of a hand-held device, cable, reusable sensor, charging station and rechargeable battery. These features enable clinicians to quickly and cost-effectively identify at-risk patients, who can then be continuously monitored with the InSpectra ™ StO2 Tissue Oxygenation Monitor (model 650). Used together, these two products help reduce the time to critical actions and help identify the endpoints of resuscitation."Having the ability to quickly assess if a patient has inadequate tissue oxygenation, especially when vital signs are not indicating a problem, can speed treatment decisions," said Didier Payen de la Garanderie, MD, PhD, Chief of Anesthesia, Critical Care and Emergency Medicine at Hopital Lariboisiere, Paris, France. "This is an exciting innovation for pre-hospital and emergency medicine patients." Evidence in favor of incorporating StO2 into clinical practice continues to grow. "Multiple clinical studies demonstrate that patients with low StO2 are at risk of poor clinical outcomes and that measurement of StO2 helps detect problems other vital signs do not," said Rick Penn, President of Hutchinson Technology's BioMeasurement Division. "In addition, recent research suggests that using StO2 to guide patient treatment results in improved clinical outcomes as well as economic benefits in the form of shorter length of stays in the ICU and the hospital."
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV